Nucleate Rhode Island - Inside Clinical Translation
Join Nucleate Rhode Island for an engaging panel discussion on what it takes to successfully turn a scientific breakthrough into an investigational new drug. What steps can companies take to de-risk their assets? How is the balance between development speed and drug safety found? How early should someone start thinking about their commercialization strategy? And how is success even defined, anyway?
Tune in on Zoom this Wednesday to hear answers from two pharmaceutical R&D experts: Michael Grass, PhD, and Stan Spence, PhD!
About the Host:
Nucleate is a 501(c)(3) nonprofit organization dedicated to empowering the next generation of biotech leaders. With chapters spanning 41 geographic regions and participation from over 280 academic institutions, Nucleate sparks new intellectual communities and embeds emerging talent within a global biotech community. Through open-access educational programming, Nucleate helps democratize biotech innovation — removing barriers and helping founders concentrate on building transformational technologies. Visit www.nucleate.xyz for more information, and visit https://nucleate.xyz/privacy-policy/ to read our privacy policy.
We want to thank our HQ supporters for championing our open-access mission and empowering the next generation of biotech entrepreneurs!
Platinum: Eli Lilly and Company, Genentech, Alnylam Pharmaceuticals, MilliporeSigma
Philanthropic Support: Lyda Hill Philanthropies
Preferred Partners: Pillar VC, Amino Collective, Excedr, Mercury, Brex, Fedsprout
In-Kind Support: AcademicLabs, Lens.org, SynBioBeta